Updated Results From Phase I Trial of AMG 420, an Anti-BCMA Bispecific T-Cell Engager, in Patients With Relapsed/Refractory Multiple Myeloma

May 31 - June 4, 2019; Chicago, Illinois
The BiTE construct AMG 420 induces rapid clinical responses, including MRD negativity, in patients with relapsed/refractory multiple myeloma.
Format: Microsoft PowerPoint (.ppt)
File Size: 212 KB
Released: June 4, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Celgene Corporation

Related Content

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Gain key clinical insights from Sagar Lonial, MD on anti-BCMA ADCs for R/R MM, from Clinical Care Options (CCO)

Sagar Lonial, MD Released: September 10, 2021

Gain key clinical insights from Suzanne Lentzsch, MD, PhD on anti-BCMA bispecific antibodies for R/R MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Gain key clinical insights from Thomas G. Martin, MD on anti-BCMA CAR T-cell therapy for R/R MM, from Clinical Care Options (CCO)

Thomas G. Martin, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue